Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

Sarepta Therapeutics Inc. landed a deal with investors to restructure around $700 million of debt, giving the company a ...

Certain Sarepta Therapeutics Inc. insiders were accused in a stockholder lawsuit of reaping a combined $6.2 million selling ...

Discover the challenges and opportunities for Keros Therapeutics, Inc., including FDA designations, partnerships, and ...

Morning. Today, we see fallout from the FDA’s rejection of Replimune’s melanoma drug affecting another biotech, learn how Sarepta’s decision-making has affected a patient population that hasn’t always ...

Barclays says Sarepta’s (SRPT) debt refinancing was done on largely favorable terms and has minimized the company’s liquidity concerns. Barclays ...

Following recent FDA-related challenges and cost-cutting initiatives, Sarepta has secured an extension on a large chunk of ...

The debt refinancing follows the firm's recent trouble with the FDA and efforts to refocus its pipeline priorities, preserve resources, and meet financial obligations.

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the ...